Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Legius, E; Messiaen, L; Wolkenstein, P; Pancza, P; Avery, RA; Berman, Y; Blakeley, J; Babovic-Vuksanovic, D; Cunha, KS; Ferner, R; et al.
Genetics in Medicine.
2021;
23:1506-1513.
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.
Payne, JM; Haebich, KM; MacKenzie, R; Walsh, KS; Hearps, SJ C; Coghill, D; Barton, B; Pride, NA; Ullrich, NJ; Tonsgard, JH; et al.
Journal of Attention Disorders.
2021;
25:1177-1186.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al.
Journal of Clinical Oncology.
2021;
39:797-806.
Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir, S; Shah, S; Shapiro, S; Koehler, A; Mahammedi, A; Samy, RN; Zuccarello, M; Schorry, E; Sengupta, S.
International Journal of Molecular Sciences.
2021;
22.
Are Some Randomized Clinical Trials Impossible?.
Rios, JJ; Richards, BS; Stevenson, DA; Oberlander, B; Viskochil, D; Gross, AM; Dombi, E; Widemann, BC; Plotkin, SR; May, CJ; et al.
Journal of Pediatric Orthopaedics.
2021;
41:e90-e93.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse, LJ; Jordan, JT; Radtke, HB; Rosser, T; Schorry, E; Ullrich, N; Viskochil, D; Knight, P; Plotkin, SR; Yohay, K.
Oncologist.
2020;
25:e1109-e1116.
Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1.
Ottenhoff, MJ; Rietman, AB; Mous, SE; Plasschaert, E; Gawehns, D; Brems, H; Oostenbrink, R; van Minkelen, R; Nellist, M; Schorry, E; et al.
Genetics in Medicine.
2020;
22:889-897.
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
Payne, JM; Hearps, SJ C; Walsh, KS; Paltin, I; Barton, B; Ullrich, NJ; Haebich, KM; Coghill, D; Gioia, GA; Cantor, A; et al.
Annals of Clinical and Translational Neurology.
2019;
6:2555-2565.
Health Supervision for Children With Neurofibromatosis Type 1.
Miller, DT; Schorry, E; Ullrich, NJ; Viskochil, D; Korf, BR; Chen, E; Trotter, TL; Berry, SA; Burke, LW; Geleske, TA; et al.
Pediatrics.
2019;
143.
Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
Koczkowska, M; Callens, T; Gomes, A; Sharp, A; Chen, Y; Hicks, AD; Aylsworth, AS; Azizi, AA; Basel, DG; Bellus, G; et al.
Genetics in Medicine.
2019;
21:867-876.